Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
July 08 2020 - 8:05AM
Guardant Health, Inc. (Nasdaq: GH) today announced a strategic
collaboration with Janssen Biotech, Inc. (Janssen) to pursue
regulatory approval and commercialization of the Guardant360® CDx
as a companion diagnostic for amivantamab, an investigational
EGFR-MET bispecific antibody being studied in the treatment of
non-small cell lung cancer (NSCLC). The agreement covers the United
States, Canada, Japan, and Europe.
“Studies continue to show that the full promise of
personalized medicine remains out of reach for the majority of
patients with advanced non-small cell lung cancer who are
not receiving complete genotyping before starting therapy, thus
impeding their treatment with the most appropriate therapy,” said
AmirAli Talasaz, Ph.D., Guardant Health President. “Our Guardant360
liquid biopsy has been shown to overcome the barriers associated
with tissue, and increase genotyping rates, which we believe will
ultimately help ensure that all patients who are eligible for
potentially life-changing therapies are identified from the
start.”
The Guardant360 blood test is increasingly being used to guide
treatment in metastatic cancer, as the number of treatment-relevant
genomic alterations continues to grow. Using next-generation
sequencing, the Guardant360 test analyzes 74 genes using cell-free
tumor DNA from patient blood samples. The Guardant360 test is
broadly covered by Medicare for use across the vast majority of
advanced solid tumors, including patients with metastatic
NSCLC.
About Guardant HealthGuardant
Health is a leading precision oncology company focused on
helping conquer cancer globally through use of its proprietary
blood tests, vast data sets and advanced analytics. The Guardant
Health Oncology Platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has launched liquid biopsy-based Guardant360 and
GuardantOMNI® tests for advanced stage cancer patients. These tests
fuel development of its LUNAR program, which aims to address the
needs of early stage cancer patients with neoadjuvant and adjuvant
treatment selection, cancer survivors with surveillance,
asymptomatic individuals eligible for cancer screening and
individuals at a higher risk for developing cancer with early
detection.
Forward-looking
StatementsThis press release contains
forward-looking statements within the meaning of federal securities
laws, including statements regarding the regulatory approvals to be
pursued by Guardant Health under its collaboration with Janssen
Biotech and the potential benefits and advantages of the
Guardant360 test, which involve risks and uncertainties that could
cause the actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking
statements. Such risks and uncertainties include those discussed
under the caption “Risk Factors” in Guardant Health’s Annual Report
on Form 10-K for the year ended December 31, 2019, its
Quarterly Report on Form 10-Q for the period ended March 31, 2020,
and in its other reports filed with the Securities and
Exchange Commission. These forward-looking statements are based on
current expectations, forecasts, assumptions and information
available to Guardant Health as of the date hereof, and
actual outcomes and results could differ materially from these
statements due to a number of factors, and Guardant Health
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Guardant Health’s views
as of any date subsequent to the date of this press release.
Investors are urged not to rely on any forward-looking statement in
reaching any conclusion or making any investment decision about any
securities of Guardant Health.
Investor Contact: Carrie
Mendivil investors@guardanthealth.com
Media Contact: Anna Czene
press@guardanthealth.com
Becky Lauer becky.lauer@uncappedcommunications.com
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Apr 2024 to May 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From May 2023 to May 2024